IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes

Figures

• 

  Figure 1.. Flowchart of study procedures of the 2 studies. A, The participant flow examining participants with type 2 diabetes (T2D) and obesity being treated for 4 or 8 weeks. B, The second part of our 2-fold study design, involving participants with T2D, obesity, and heart failure with preserved ejection fraction (HFpEF), all being treated for 12 weeks.

• 

  Figure 2.. The effect of ninerafaxstat on metabolic readouts. Part 1 involved participants with type 2 diabetes (T2D) and obesity but without heart failure with preserved ejection fraction (HFpEF). A through C, magnetic resonance spectroscopy results. A, The increase in resting myocardial phosphocreatine-to-ATP ratio (PCr/ATP; primary outcome). B and C, A before and after spectrum, respectively. D, The drop in myocardial triglyceride content after treatment. Part 2 involved participants with T2D and obesity and HFpEF. E, The increase in resting myocardial PCr/ATP (primary outcome). F and G, A before and after spectrum, respectively. H, The increase in myocardial triglyceride content after treatment.

• 

  Figure 3.. The effect of ninerafaxstat on cardiac morphology and function. Part 1 involved participants with type 2 diabetes (T2D) and obesity without heart failure with preserved ejection fraction (HFpEF). A through D, Left ventricular (LV) end-diastolic volume (EDV), left ventricular stroke volume (LVSV), LV mass, and left ventricular ejection fraction (LVEF). E through H, Diastolic filling rates and strain. I through K, Right ventricular (RV) EDV, end-systolic volume (ESV), right ventricular SV (RVSV), and right ventricular ejection fraction (RVEF). l shows left atrial (LA) size. Part 2 involved participants with T2D and obesity and HFpEF. M through P, LV size and systolic function. Q, LV mass.